(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 75.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Connect Biopharma Holdings's revenue in 2026 is $2,953,000.On average, 9 Wall Street analysts forecast CNTB's revenue for 2026 to be $523,064,611, with the lowest CNTB revenue forecast at $178,972,986, and the highest CNTB revenue forecast at $1,183,602,138. On average, 9 Wall Street analysts forecast CNTB's revenue for 2027 to be $1,118,738,599, with the lowest CNTB revenue forecast at $685,034,533, and the highest CNTB revenue forecast at $1,699,361,728.
In 2028, CNTB is forecast to generate $854,309,476 in revenue, with the lowest revenue forecast at $135,772,610 and the highest revenue forecast at $1,302,623,582.